Delayed return to profitability due to accumulated losses from prior fiscal years, new customer acquisition and the resurgence of infectious diseases
First written in FY2023. 3 of 5 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「During the interim accounting period from 1 January 2026 to 30 June 2026, there were no material changes in the business and other risks described in the annual securities report for the previous fiscal year.」
No material change was reported in the risk of delayed profitability due to historical losses, new-customer acquisition and a resurgence of infectious diseases. - FY2025-H1RestatedAnnual report
「During the interim accounting period from 1 January 2025 to 30 June 2025, there were no material changes in the business and other risks described in the annual securities report for the previous fiscal year.」
No material change was reported in the risk of delayed profitability due to historical losses, new-customer acquisition and a resurgence of infectious diseases. - FY2024-H1RestatedAnnual report
「Operating profit was ¥87.422 million, ordinary profit was ¥69.471 million and interim net profit was ¥45.441 million.」
The interim period was also profitable, following the quarter, but this does not demonstrate full-year profitability. - FY2024-Q1MitigatedAnnual report
「Revenue for the first quarter cumulative period was ¥548.069 million.」
The first quarter recorded quarterly net profit of ¥1.743 million, indicating reduced risk of delayed profitability on a quarterly basis, but not demonstrating full-year profitability. - FY2023First statedAnnual report
「The Company recorded ordinary losses and net losses from the fiscal year ended December 2020 through the fiscal year ended December 2022. This was due to lower revenue resulting from the impact of infectious diseases and aggressive investment to expand the business.」
Historical losses are described as events that actually occurred, while stalled new-customer acquisition and a resurgence of infectious diseases are identified as risks. The Company returned to profitability in fiscal 2023.